Por favor, use este identificador para citar o enlazar este ítem:
10.14670/HH-11-695
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Lee, Kyoungmin | - |
dc.contributor.author | Kim, Dong Geon | - |
dc.contributor.author | Yang, Hee Kyoung | - |
dc.contributor.author | Nam, Do-Hyun | - |
dc.date.accessioned | 2021-04-16T10:55:11Z | - |
dc.date.available | 2021-04-16T10:55:11Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Histology and Histopathology, vol.31, nº3, (2016) | es |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.uri | http://hdl.handle.net/10201/106666 | - |
dc.description.abstract | Despite years of research into its pathobiology and continuing clinical trials for novel therapies, the prognosis for patients with glioblastoma (GBM) remains dismal. An important obstacle against treatment efficacy may be a high degree of intra- and inter-tumoral heterogeneity within GBMs, which may be caused by the presence of self-renewing GBM stem cells (GSCs). Recent advances in multi-omics technology introduce new possibilities for applying personalized strategies to GBM therapy. As drug discovery is accelerating with the transition from non-selective, cytotoxic therapy to a precision, targeted approach, the appropriate in vivo platform for GBM is critical for validating drug targets and prioritizing candidates for clinical studies, for co-development of companion diagnostics and, ultimately, for drug approval. Here we will describe GBM orthotopic patient-derived xenografts (PDXs) as more useful, clinically relevant resources for individually tailored strategies for GBM. | es |
dc.format | application/pdf | es |
dc.format.extent | 15 | es |
dc.language | eng | es |
dc.publisher | Universidad de Murcia. Departamento de Biología Celular e Histología | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Glioblastoma | es |
dc.subject | Personalized medicine | es |
dc.subject | Tumor heterogeneity | es |
dc.subject | Glioblastoma stem cells | es |
dc.subject | Tumor microenvironment | es |
dc.subject | Patient-derived xenografts | es |
dc.subject | Orthotopic | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología | es |
dc.title | Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | 10.14670/HH-11-695 | - |
Aparece en las colecciones: | Vol.31, nº3 (2016) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Lee-31-269-283-2016.pdf | 3,73 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons